News

Novartis has reported result of Tasigna Phase III clinical trial. In the study, Tasigna (nilotinib) demonstrated greater efficacy over Glivec (imatinib) in the treatment of adult patients with

Tranzyme Pharma (Tranzyme ) has entered into a strategic collaboration agreement with Bristol-Myers Squibb, to discover, develop and commercialise macrocyclic compounds directed against targets of interest to Bristol-Myers

Allos Therapeutics (Allos) has provided updated data from its ongoing dose finding phase 1 study of Folotyn (pralatrexate injection) in patients with relapsed or refractory cutaneous T-cell lymphoma

FDA has selected MasterControl from SynCardia Systems as the new quality management system for the Food and Drug Administration (FDA). MasterControl also provides the quality management system for

Eli Lilly (Lilly) has agreed to a one-year renewal of its drug discovery collaboration with Applied NeuroSolutions. Lilly is expected to pay $250,000 to Applied NeuroSolutions for the

Eli Lilly and Company (Lilly) has announced the availability of a first smaller insulin vial in the US, containing 3ml (300 units) of insulin, for people with diabetes

Viral Genetics has entered into an exclusive license agreement with the University of Colorado to develop cancer therapies based on the work of Karen Newell, a professor of

Millipore has introduced Scepter, a handheld, automated cell counter, at the American Society of Cell Biology Annual Meeting in San Diego. Scepter miniaturizes Coulter cell counting technology found

QuantRx Biomedical has introduced new point-of-care (POC) diagnostic reader device, Q-Reader, at MEDICA 2009 in Dusseldorf, Germany. The Q-Reader addresses the performing of advanced medical diagnostic procedures where